MABFC Trademark
MABFC is a USPTO trademark filed by LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES. Status: Cancelled.
Trademark Facts
| Mark | MABFC |
|---|---|
| Serial Number | 79206752 |
| Registration Number | 5415118 |
| Status | Cancelled |
| Filing Date | 2016-12-14 |
| Registration Date | 2018-03-06 |
| Mark Type | Combined |
| Nice Classes | 005 (Pharmaceuticals), 042 (Software & IT) |
| Owner | LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES |
| Attorney of Record | Monte L. Falcoff/Jessica S. Sachs |
| Prosecution Events | 33 |
| Latest Event | INTR on 2025-05-20 |
Goods & Services
Pharmaceutical products and preparations for the treatment of cancer, autoimmune disorders, inflammatory disorders, viral and bacterial infections, blood diseases; medicines for cancer, autoimmune disorders, inflammatory disorders, viral and bacterial infections, blood diseases; protein supplements; diagnostic kits consisting primarily of monoclonal antibodies and fragment crystallizable proteins, buffers, and reagents for use in disease testing; Scientific and technological services, namely, scientific research and analysis in the field of monoclonal antibodies and fragment crystallizable proteins; design and development of medical products, namely, pharmaceutical compositions of monoclonal antibodies and fragment crystallizable proteins; scientific study and research in the field of the prevention and the treatment of cancer, autoimmune disorders, inflammatory disorders, viral and bacterial infections, blood diseases; research and development in the field of the prevention and the treatment of cancer, autoimmune disorders, inflammatory disorders, viral and bacterial infections, blood diseases; cellular and molecular biological research; design and development of medical products, namely, pharmaceutical compositions of monoclonal antibodies and fragment crystallizable proteins; testing, inspection or research of pharmaceuticals; medical and scientific research, namely, conducting clinical trials for others; consulting in the field of medical research; engineering; genetic engineering; platform technology, namely, protein expression platform for research and development of pharmaceuticals; platform technology, namely, protein expression platform for manufacturing protein-based therapeutics; medical and scientific research of recombinant protein platform technologies designed to lead to new human vaccines, therapeutic proteins and antibodies; laboratory services in the field of monoclonal antibodies